The @-week reduction in vasomotor symptom frequency from baseline relative to placebo was similar for escitalopram at -@ per day ( @ % confidence interval -LSB- CI -RSB- -@ to -@ ) , low-dose E@ at -@ ( @ % CI -@ to -@ ) , and venlafaxine at -@ ( @ % CI -@ to -@ ) ; vasomotor symptom bother reduction was minimal and did not vary across these three pharmacologic interventions ( mean -@ to -@ relative to placebo ) .